20240043445. Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors simplified abstract (SignalRx Pharmaceuticals, Inc.)
Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors
Organization Name
SignalRx Pharmaceuticals, Inc.
Inventor(s)
Guillermo A. Morales of Oro Valley AZ (US)
Joseph R. Garlich of Cape Coral FL (US)
Donald L. Durden of Charlotte NC (US)
Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240043445 titled 'Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors
Simplified Explanation
The invention relates to compounds and methods of treating various diseases including cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atherosclerosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-dependent disorder. This is achieved by modulating biological processes through the inhibition of cell cycle checkpoint targets CDKs, PI3 kinase, and/or bromodomain protein binding to substrates. The compounds of formula 1-v1 (or pharmaceutically acceptable salts thereof) are administered for this purpose.
- The invention involves compounds and methods for treating diseases such as cancer, sepsis, autoimmune disease, viral infection, diabetes, obesity, and inflammatory disease.
- The compounds modulate biological processes by inhibiting cell cycle checkpoint targets CDKs, PI3 kinase, and/or bromodomain protein binding to substrates.
- The compounds of formula 1-v1 (or pharmaceutically acceptable salts thereof) are administered for the treatment of these diseases.
Potential Applications
The technology has potential applications in the following areas:
- Cancer treatment
- Treatment of non-cancer proliferative diseases
- Treatment of sepsis
- Treatment of autoimmune diseases
- Treatment of viral infections
- Treatment of atherosclerosis
- Treatment of type 1 or 2 diabetes
- Treatment of obesity
- Treatment of inflammatory diseases
- Treatment of myc-dependent disorders
Problems Solved
The technology addresses the following problems:
- Lack of effective treatments for various diseases including cancer, sepsis, autoimmune diseases, viral infections, diabetes, obesity, and inflammatory diseases.
- Limited options for modulating biological processes involved in disease progression.
- Inefficient inhibition of cell cycle checkpoint targets CDKs, PI3 kinase, and bromodomain protein binding to substrates.
Benefits
The technology offers the following benefits:
- Improved treatment options for a wide range of diseases.
- Modulation of biological processes involved in disease progression.
- Effective inhibition of cell cycle checkpoint targets CDKs, PI3 kinase, and bromodomain protein binding to substrates.
- Potential for personalized medicine approaches based on the specific disease being treated.
Original Abstract Submitted
the invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atherosclerosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-dependent disorder including by modulating biological processes by the inhibition of cell cycle checkpoint targets cdks, and/or pi3 kinase, and/or bromodomain protein binding to substrates, comprising the administration of a compound(s) of formula 1-v1 (or pharmaceutically acceptable salts thereof) as defined herein.
